Important note: Information in this article was accurate in April 2001. The state of the art may have changed since the publication date.AIDSWEEKLY Plus; Monday, April 16, 2001
N.R. Saltmarsh, Staff Medical Writer
NewsRx - A prospective study of human immunodeficiency virus type 1 (HIV-1) incidence among high-risk cohorts lends support to the idea that HIV-1 vaccine trials would be appropriate and welcomed in these populations in the United States.
"Questions exist about whether testing of preventive HIV-1 vaccines, which will require rapid recruitment and retention of cohorts with high HIV-1 seroincidence, is feasible in the United States," said G.R. Seage, III, and colleagues in the HIVNET Vaccine Preparedness Study group at the Harvard School of Public Health.
They conducted a prospective cohort study in 1995-1997 among 4,892 people at high risk for HIV infection in nine U.S. cities.
Of the 88% of study participants responding, 90 had HIV-1 infection, for an overall rate of 1.31/100 person-years. Men who had sex with men were at greatest risk (1.55/100 person-years), followed by male intravenous (IV) drug users (0.38/100 person-years), female IV drug users (1.24/100 person-years), and heterosexual women (01.13/100 person-years), reported Seage et al.
Men who had sex with men who reported unprotected anal intercourse, participants who were definitely willing to enroll in an HIV vaccine trial, and women who used crack cocaine had the highest incidence of HIV ("Are U.S. populations appropriate for trials of human immunodeficiency virus vaccine? The HIVNET Vaccine Preparedness Study," Am J Epidemiol 2001 Apr 1;153(7):619-27.
"Cohorts with HIV-1 seroincidence rates appropriate for HIV-1 vaccine trials can be recruited, enrolled, and retained," concluded Seage et al.
For more information about this study contact G.R. Seage III, Abt Associates Inc., and Department of Epidemiology, Harvard School of Public Health, Boston, MA, USA.
A search at www.NewsRx.net for the term "AIDS and HIV vaccine" returned more than 170 articles in six specialized reports.
Key points reported in this study include:
This article was prepared by AIDS Weekly editors from staff and other reports.
010423
AW010410
Copyright © 2001 - Charles Henderson, Publisher. All rights Reserved. Permission to reproduce granted to AEGIS by Charles W. Henderson. Authorization to reproduce for personal use granted granted by C. W. Henderson, Publisher, provided that the fee of US$4.50 per copy, per page is paid directly to the Copyright Clearance Center, 27 Congress Street, Salem, Massachusetts 01970, USA. Published by Charles Henderson, Publisher. Editorial & Publishing Office: P.O. Box 5528, Atlanta, GA 30307-0528 / Telephone: (800) 633-4931; Subscription Office: P.O. Box 830409, Birmingham, AL 35283-0409 / FAX: (205) 995-1588 http://www.newsrx.net
AEGiS is made possible through unrestricted grants from Boehringer Ingelheim, iMetrikus, Inc., the National Library of Medicine, and donations from users like you. Always watch for outdated information. This article first appeared in 2001. This material is designed to support, not replace, the relationship that exists between you and your doctor.
AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.
Copyright ©1990,2001. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content.